Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 10, 2026

NewcelX and Eledon partner for NCEL-101 programme

NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D).

Tegoprubart is a monoclonal antibody developed to regulate immune pathways in transplant rejection. Credit: Corona Borealis Studio / Shutterstock.com.